09-04-2025
This Biotech Is Ripping Following Phase 1b Trial Announcement
A biotech company based out of Massachusetts is turning heads so far during Wednesday's session after the company announced its Safety Monitory Committee recommended dose escalation in its Phase 1b trial of PH-762.
Naturally traders rushed to buy up shares of Phio Pharmaceuticals Corp. (Nasdaq:PHIO), pushing the micro cap up to $2.73/share (+170.30%) at the early session high. This move could be an indication of a potential breakout as this stock fights to get out of the year-long downtrend it has been stuck in.
Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others.
Copyright © 2025 All rights reserved. Republication or redistribution of content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
View more of this article on
About Media, Inc.:
Founded in 1999, is one of North America's leading platforms for micro-cap insights.
Catering to both Canadian and U.S. markets, we provide a wealth of resources and expert content designed for everyone—from beginner investors to seasoned traders.
is rapidly gaining recognition as a leading authority in the micro-cap space, with our insightful content prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals.
Want to showcase your company's story to a powerful network of investors? We can help you elevate your message and make a lasting impact. Contact us today.
Contact:
Media, Inc.
